Earnings call transcript: Claritev’s Q1 2026 shows strong revenue growth

Claritev reported Q1 2026 revenue of $244.7 million, up 5.8% year over year, with adjusted EBITDA of $146.9 million (+3.4%) and unlevered free cash flow of $36.8 million (+181%). Management raised the low end of full-year revenue guidance to $985 million-$1 billion while keeping adjusted EBITDA guidance at $605 million-$615 million, but the stock fell 9.29% premarket to $24.01. The quarter was driven by 8.4% growth in Claims Intelligence and strong ACV bookings of $44.1 million, though investor reaction was negative despite the operational beat.

Analysis

The market is not pricing CTEV on this print; it is pricing the credibility of the forward bridge. The core issue is timing: bookings and new vertical wins are being pulled forward now, but meaningful revenue conversion is delayed into 2027, so the stock is vulnerable to any near-term deceleration in reported growth even if the pipeline is healthy. That creates a classic setup where the first derivative of fundamentals improves while the second derivative of expectations worsens.

The more important second-order effect is mix. As services and public-sector/provider wins scale, headline growth becomes less predictive of margin than the degree of pull-through into high-margin core products. If management can actually convert service relationships into higher-value horizontal attach, the market is underestimating the medium-term EBITDA durability; if not, the incremental revenue will dilute economics and cap multiple expansion. That tension explains why good results can still trade poorly: investors are trying to distinguish “strategic diversification” from “lower-quality growth.”

The contrarian read is that the selloff may be overdone if the Q1 ACV pace holds and if the company keeps turning AI-enabled automation into real labor leverage rather than just narrative. But the setup is fragile because the equity is already telling you it wants proof, not promises. Any slip in Q2 sequential revenue, bookings conversion, or margin trajectory would likely hit the stock harder than usual because positioning is probably momentum-driven after the recent rebound.

Key Decisions for Investors

• Buy CTEV on a 2-4 week pullback only if it holds the premarket gap-down lows; upside is a re-rate back toward recent highs if the market regains confidence in bookings conversion, but downside is large if Q2 guide-through weakens.
• Use a call spread in CTEV for the next 3-6 months rather than common stock; the thesis is upside from sentiment repair and ACV visibility, but defined risk is preferable given guidance skepticism and prior volatility.
• Pair long CTEV / short a healthcare services peer with slower organic growth and less AI leverage over the next 1-2 quarters; this isolates the stock-specific catalyst from sector beta while expressing the view that execution quality will matter more than the headline mark.
• If CTEV rallies into the next print without evidence of faster revenue conversion, fade strength with a tactical short; the risk/reward worsens if the market starts focusing on 2027 timing gaps instead of 2026 bookings.
• Watch for confirmation in the next quarter that services are pulling through high-margin products; if attach rates improve, add to longs, because that is the path to multiple expansion rather than just top-line noise.